TNF-α inhibitors: are they carcinogenic?

Figures & data

Table 1 Diseases in which tumor necrosis factor-α (TNF-α is implicated, and clinical uses of TNF-α inhibitors

Diseases in which TNF-α is implicated in the pathophysiology	TNF-α inhibitors use in clinical practice	Reported malignancies associated with anti-TNF agent use in these conditions
Rheumatoid arthritis	Etanercept, adalimumab	Lymphoma, leukemia, solid organ malignancies, nonmelanoma skin cancer
Psoriasis	Infliximab, etanercept	Lymphoma, leukemia, nonmelanoma skin cancer, melanoma
Crohn’s disease	Infliximab in severe disease refractory to other interventions	Lymphoma, leukemia, solid organ malignancies
Ankylosing spondylitis	Etanercept, infliximab	–
Asthma	No TNF-α inhibitors in clinical use	–